BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/25/2023 9:36:53 AM | Browse: 464 | Download: 1508
 |
Received |
|
2023-06-15 06:59 |
|
Peer-Review Started |
|
2023-06-15 07:02 |
|
First Decision by Editorial Office Director |
|
2023-08-26 16:53 |
|
Return for Revision |
|
2023-08-26 16:53 |
|
Revised |
|
2023-09-08 14:58 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-09-14 02:53 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-09-14 08:32 |
|
Articles in Press |
|
2023-09-14 08:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-09-19 05:39 |
|
Publish the Manuscript Online |
|
2023-09-25 09:07 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Control Study |
| Article Title |
Leukocyte immunoglobulin-like receptor B2 overexpression as a promising therapeutic target and noninvasive screening biomarker for colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qian-Qian Wang, Lei Zhou, Geng Qin, Chang Tan, Yuan-Chen Zhou and Shu-Kun Yao |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key Development Plan for Precision Medicine Research |
2017YFC0910002 |
|
| Corresponding Author |
Shu-Kun Yao, MD, PhD, Professor, Department of Gastroenterology, Peking University China-Japan Friendship School of Clinical Medicine, No. 2 Yinghua East Road, Chaoyang District, Beijing 100029, China. shukunyao@126.com |
| Key Words |
Colorectal cancer; Leukocyte immunoglobulin-like receptor B2; Angiopoietin-like protein 2; Therapeutic target; Noninvasive screening biomarker |
| Core Tip |
Based on prior proteomic research rather than simple data mining, this study innovatively proposed and validated that leukocyte immunoglobulin-like receptor B2 (LILRB2) and its ligand, the angiopoietin-like protein 2 protein, are significantly overexpressed in colorectal cancer (CRC) and closely associated with tumour progression and a poor prognosis. In addition, this study is the first to propose that serum LILRB2 concentration can be used as a novel screening biomarker with a sensitivity of 89.74%, a specificity of 88.89% and an accuracy rate of 89.63% for the diagnosis of CRC. The sensitivity and accuracy were significantly higher than those of carcinoembryonic antigen and carbohydrate antigen 19-9. Therefore, LILRB2 could be a promising therapeutic target and noninvasive screening biomarker for CRC. |
| Publish Date |
2023-09-25 09:07 |
| Citation |
Wang QQ, Zhou L, Qin G, Tan C, Zhou YC, Yao SK. Leukocyte immunoglobulin-like receptor B2 overexpression as a promising therapeutic target and noninvasive screening biomarker for colorectal cancer. World J Gastroenterol 2023; 29(37): 5313-5326
|
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i37/5313.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i37.5313 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
